Natural Acquisition of Immunity to Plasmodium vivax. Epidemiological Observations and Potential Targets

Advances in Parasitology

Volumn 81, Issue , 2013, Pages 77-131

  Mueller, Ivo ^a,b   Galinski, Mary R ^c   Tsuboi, Takafumi ^d   Arevalo Herrera, Myriam ^e   Collins, William E ^f   King, Christopher L ^g  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF BARCELONA   (Spain)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EHIME UNIVERSITY   (Japan)

^e Caucaseco Scientific Research Center   (Colombia)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunity; Malaria; Plasmodium falciparum; Plasmodium vivax

Indexed keywords

MEMBRANE ANTIGEN; PARASITE ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; CELL INVASION; DISEASE TRANSMISSION; ERYTHROCYTE MEMBRANE; EXPERIMENTAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; MALARIA FALCIPARUM; MEMBRANE; NONHUMAN; PARASITE IMMUNITY; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RELAPSE; SPOROZOITE; ANIMAL; IMMUNOLOGY; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 84873205900     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407826-0.00003-5     Document Type: Chapter

References (348)

1. Acharya P., et al. Clinical proteomics of the neglected human malarial parasite Plasmodium vivax. PLoS One 2011, 6(10):e26623.
2. Adams J.H., et al. The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites. Cell 1990, 63(1):141-153.
3. Adams J.H., et al. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(15):7085-7089.
4. Aidoo M., et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995, 345(8956):1003-1007.
5. Aikawa M., Miller L.H., Rabbege J. Caveola-vesicle complexes in the plasmalemma of erythrocytes infected by Plasmodium vivax and P cynomolgi. Unique structures related to Schuffner's dots. Am. J. Pathol. 1975, 79(2):285-300.
6. Aikawa M. Parasitological review. Plasmodium: the fine structure of malarial parasites. Exp. Parasitol. 1971, 30(2):284-320.
7. Akinyi S., et al. A 95 kDa protein of Plasmodium vivax and P. cynomolgi visualized by three-dimensional tomography in the caveola-vesicle complexes (Schuffner's dots) of infected erythrocytes is a member of the PHIST family. Mol. Microbiol. 2012, 84(5):816-831.
8. Allison A.C., Eugui E.M. The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. Annu. Rev. Immunol. 1983, 1:361-392.
9. Alves F.P., et al. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am. J. Trop. Med. Hyg. 2002, 66(6):641-648.
10. Amino R., et al. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe. 2008, 3(2):88-96.
11. Anstey N.M., et al. The pathophysiology of vivax malaria. Trends Parasitol. 2009, 25(5):220-227.
12. Arevalo-Herrera M., et al. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol. 2002, 24(3):161-169.
13. Arevalo-Herrera M., et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am. J. Trop. Med. Hyg. 2005, 73(Suppl. 5):25-31.
14. Arevalo-Herrera M., et al. Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia. Am. J. Trop. Med. Hyg. 2005, 73(Suppl. 5):38-43.
15. Arevalo-Herrera M., et al. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein. Am. J. Trop. Med. Hyg. 2011, 84(Suppl. 2):35-42.
16. Arevalo-Herrera M., et al. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am. J. Trop. Med. Hyg. 2011, 84(Suppl. 2):21-27.
17. Arevalo-Herrera M., Chitnis C., Herrera S. Current status of Plasmodium vivax vaccine. Hum. Vaccin 2010, 6(1):124-132.
18. Artavanis-Tsakonas K., et al. Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J. Immunol. 2003, 171(10):5396-5405.
19. Baer K., et al. Kupffer cells are obligatory for Plasmodium yoelii sporozoite infection of the liver. Cell. Microbiol. 2007, 9(2):397-412.
20. Baird J.K., et al. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am. J. Trop. Med. Hyg. 1991, 45(1):65-76.
21. Baird J.K., et al. Onset of clinical immunity to Plasmodium falciparum among Javanese migrants to Indonesian Papua. Ann. Trop. Med. Parasitol. 2003, 97(6):557-564.
22. Baird J.K. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol. Today 1995, 11(3):105-111.
23. Balfour M.C. Malaria studies in Greece. Am. J. Trop. Med. Hyg. 1935, 15:301-329.
24. Bang G., et al. Pre-clinical assessment of novel multivalent MSP3 malaria vaccine constructs. PLoS One 2011, 6(12):e28165.
25. Barbedo M.B., et al. Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivax. Mem. Inst. Oswaldo Cruz 2007, 102(3):335-339.
26. Barnwell J.W., Galinski M.R. Plasmodium vivax: a glimpse into the unique and shared biology of the merozoite. Ann. Trop. Med. Parasitol. 1995, 89(2):113-120.
27. Barnwell J.W., et al. Plasmodium vivax: malarial proteins associated with the membrane-bound caveola-vesicle complexes and cytoplasmic cleft structures of infected erythrocytes. Exp. Parasitol. 1990, 70(1):85-99.
28. Barnwell J.W., et al. Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. Exp. Parasitol. 1999, 91(3):238-249.
29. Baruch D.I. Adhesive receptors on malaria-parasitized red cells. Baillieres Best Pract. Res. Clin. Haematol. 1999, 12(4):747-761.
30. Batchelor J.D., Zahm J.A., Tolia N.H. Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat. Struct. Mol. Biol. 2011, 18(8):908-914.
31. Belard S., et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One 2011, 6(7):e22525.
32. Benet A., et al. Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in Papua New Guinea. Am. J. Trop. Med. Hyg. 2004, 71(3):277-284.
33. Bernabeu M., et al. Functional analysis of Plasmodium vivax VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 endothelial receptor. Cell. Microbiol. 2012, 14(3):386-400.
34. Bettiol E., et al. Dual effect of Plasmodium-infected erythrocytes on dendritic cell maturation. Malar. J. 2010, 9:64.
35. Betuela I., et al. Relapses contribute significantly to the risk of P. vivax infection and disease in Papua New Guinean children 1-5 years of age. J. Infect. Dis. 2012, (Epub ehead of pring).
36. Biggs B.A., et al. Antigenic variation in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(20):9171-9174.
37. Bilsborough J., Carlisle M., Good M.F. Identification of caucasian CD4 T cell epitopes on the circumsporozoite protein of Plasmodium vivax. T cell memory. J. Immunol. 1993, 151(2):890-899.
38. Blackman M.J., et al. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. 1994, 180(1):389-393.
39. Bottger E., et al. Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. PLoS One 2012, 7(3):e33774.
40. Boudin C., et al. Plasmodium falciparum transmission blocking immunity under conditions of low and high endemicity in Cameroon. Parasite Immunol. 2004, 26(2):105-110.
41. Bousema T., Drakeley C. Plasmodium falciparum and Plasmodium vivax gametocytes - their epidemiology and infectivity and malaria control and elimination. Clin. Microbiol. Rev. 2011, 24:377-410.
42. Bousema T., et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 and Pfs48/45 in a low endemic area in Tanzania. PLoS One 2010, 5(11):e14114.
43. Bousema T., et al. Human immune responses that reduce the transmission of Plasmodium falciparum in African populations. Int. J. Parasitol. 2011, 41(3-4):293-300.
44. Boutlis C.S., Yeo T.W., Anstey N.M. Malaria tolerance-for whom the cell tolls?. Trends Parasitol. 2006, 22(8):371-377.
45. Boyd M.F. A review of studies on immunity to vivax malaria. J. Natl. Malar. Soc. 1947, 6(1):12-31.
46. Bozdech Z., et al. The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(42):16290-16295.
47. Braga E.M., et al. Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region. Am. J. Trop. Med. Hyg. 2002, 66(5):461-466.
48. Braga E.M., Fontes C.J., Krettli A.U. Persistence of humoral response against sporozoite and blood-stage malaria antigens 7 years after a brief exposure to Plasmodium vivax. J. Infect. Dis. 1998, 177(4):1132-1135.
49. Branch O., et al. Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community. Malar. J. 2005, 4:27.
50. Bueno L.L., et al. Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-119 on the innate immune response. Vaccine 2008, 26(9):1204-1213.
51. Bueno L.L., et al. Plasmodium vivax recombinant vaccine candidate AMA-1 plays an important role in adaptive immune response eliciting differentiation of dendritic cells. Vaccine 2009, 27(41):5581-5588.
52. Bueno L.L., et al. Plasmodium vivax: induction of CD4+CD25+FoxP3+ regulatory T cells during infection are directly associated with level of circulating parasites. PLoS One 2010, 5(3):e9623.
53. Bueno L.L., et al. Identification of a highly antigenic linear B cell epitope within Plasmodium vivax apical membrane antigen 1 (AMA-1). PLoS One 2011, 6(6):e21289.
54. Bueno L.L., et al. Interleukin-17 producing T helper cells are increased during natural Plasmodium vivax infection. Acta Trop. 2012, 123(1):53-57.
55. Bull P.C., et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 1998, 4(3):358-360.
56. Calvo-Calle J.M., Oliveira G.A., Nardin E.H. Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites. J. Immunol. 2005, 175(11):7575-7585.
57. Carlton J.M., et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008, 455(7214):757-763.
58. Carter R., Chen D.H. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature 1976, 263(5572):57-60.
59. Carter R. Transmission blocking malaria vaccines. Vaccine 2001, 19(17-19):2309-2314.
60. Carvalho B.O., et al. On the cytoadhesion of Plasmodium vivax-infected erythrocytes. J. Infect. Dis. 2010, 202(4):638-647.
61. Castellanos A., et al. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Mem. Inst. Oswaldo Cruz 2007, 102(3):411-416.
62. Castelli F., et al. Malaria in migrants. Parassitologia 1999, 41(1-3):261-265.
63. Cerami C., Kwakye-Berko F., Nussenzweig V. Binding of malarial circumsporozoite protein to sulfatides [Gal(3-SO4)beta 1-Cer] and cholesterol-3-sulfate and its dependence on disulfide bond formation between cysteines in region II. Mol. Biochem. Parasitol. 1992, 54(1):1-12.
64. Ceravolo I.P., et al. Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon. Am. J. Trop. Med. Hyg. 2005, 72(6):675-681.
65. Ceravolo I.P., et al. Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission. Scand. J. Immunol. 2008, 67(3):270-278.
66. Ceravolo I.P., et al. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin. Exp. Immunol. 2009, 156(3):502-510.
67. Chen N., et al. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J. Infect. Dis. 2007, 195(7):934-941.
68. Chen J.H., et al. Immunoproteomics profiling of blood stage Plasmodium vivax infection by high-throughput screening assays. J. Proteome Res. 2010, 9(12):6479-6489.
69. Chesne-Seck M.L., et al. Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites. Mol. Biochem. Parasitol. 2005, 144(1):55-67.
70. Chitnis C.E., et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J. Exp. Med. 1996, 184(4):1531-1536.
71. Chitnis C.E. Molecular insights into receptors used by malaria parasites for erythrocyte invasion. Curr. Opin. Hematol. 2001, 8(2):85-91.
72. Chootong P., et al. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect. Immun. 2010, 78(3):1089-1095.
73. Ciuca M., Ballif L., Chelarescu-Vieru M. Immunity in malaria. Trans. R Soc. Trop. Med. Hyg. 1934, 26(6):619-622.
74. Clyde D.F. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull. World Health Organ. 1990, 68(Suppl):9-12.
75. Cockburn I.A., et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog. 2010, 6(5):e1000877.
76. Coggeshall L.T., Kumm H.W. Demonstration of passive immunity in experimental monkey malaria. J. Exp. Med. 1937, 66(2):177-190.
77. Cohen S., Mc G.I., Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
78. Coleman R.E., et al. Infectivity of asymptomatic Plasmodium-infected human populations to Anopheles dirus mosquitoes in western Thailand. J. Med. Entomol. 2004, 41(2):201-208.
79. Cole-Tobian J.L., et al. Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J. Infect. Dis. 2002, 186(4):531-539.
80. Cole-Tobian J.L., et al. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect. Immun. 2009, 77(9):4009-4017.
81. Collins W.E., Jeffery G.M. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum in patients previously infected with heterologous species of Plasmodium: effect on development of parasitologic and clinical immunity. Am. J. Trop. Med. Hyg. 1999, 61(Suppl. 1):36-43.
82. Collins W.E., Jeffery G.M. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. Am. J. Trop. Med. Hyg. 1999, 61(Suppl. 1):4-19.
83. Collins W.E., Jeffery G.M. A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am. J. Trop. Med. Hyg. 1999, 61(Suppl. 1):20-35.
84. Collins W.E., Jeffery G.M. A retrospective examination of the patterns of recrudescence in patients infected with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1999, 61(Suppl. 1):44-48.
85. Collins W.E., et al. Reinforcement of immunity in Saimiri monkeys following immunization with irradiated sporozoites of Plasmodium vivax. Am. J. Trop. Med. Hyg. 1992, 46(3):327-334.
86. Collins W.E., et al. Testing the efficacy of a recombinant merozoite surface protein MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys. Am. J. Trop. Med. Hyg. 1999, 60(3):350-356.
87. Collins W.E., Jeffery G.M., Roberts J.M. A retrospective examination of anemia during infection of humans with Plasmodium vivax. Am. J. Trop. Med. Hyg. 2003, 68(4):410-412.
88. Collins W.E., Jeffery G.M., Roberts J.M. A retrospective examination of reinfection of humans with Plasmodium vivax. Am. J. Trop. Med. Hyg. 2004, 70(6):642-644.
89. Collins W.E., Jeffery G.M., Roberts J.M. A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax. Am. J. Trop. Med. Hyg. 2004, 70(6):638-641.
90. Craig A.A., Kain K.C. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J. Infect. Dis. 1996, 174(2):373-379.
91. da Silva-Nunes M., et al. Malaria on the Amazonian frontier: transmission dynamics, risk factors, spatial distribution, and prospects for control. Am. J. Trop. Med. Hyg. 2008, 79(4):624-635.
92. Danforth H.D., et al. Sporozoites of mammalian malaria: attachment to, interiorization and fate within macrophages. J. Protozol. 1980, 27(2):193-202.
93. Del Giudice G., et al. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines. J. Immunol. 1986, 137(9):2952-2955.
94. del Portillo H.A., et al. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(9):4030-4034.
95. del Portillo H.A., et al. A superfamily of variant genes encoded in the subtelomeric region of Plasmodium vivax. Nature 2001, 410(6830):839-842.
96. Devi Y.S., et al. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. Vaccine 2007, 25(28):5166-5174.
97. Dharia N.V., et al. Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(46):20045-20050.
98. Dias S., et al. Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka. Vaccine 2011, 29(43):7491-7504.
99. D'Ombrain M.C., et al. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin. Infect. Dis. 2008, 47(11):1380-1387.
100. Doolan D.L., Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr. Mol. Med. 2006, 6(2):169-185.
101. Doolan D.L., et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008, 8(22):4680-4694.
102. Doolan D.L. Plasmodium immunomics. Int. J. Parasitol. 2011, 41(1):3-20.
103. Dutta S., et al. Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys. Infect. Immun. 2005, 73(9):5936-5944.
104. Dutta S., et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009, 4(12):e8138.
105. Earle W.C. Epidemiology of malaria in Puerto Rico. Puerto Rico J. Pub Health Trop. Med. 1939, 15:3-27.
106. Egan A.F., et al. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 1999, 21(3):133-139.
107. Faure P., et al. Protective immunity against malaria: cellular changes in the liver vary according to the method of immunization. Parasite Immunol. 1995, 17(9):469-477.
108. Fernandez-Becerra C., et al. Variant proteins of Plasmodium vivax are not clonally expressed in natural infections. Mol. Microbiol. 2005, 58(3):648-658.
109. Fernandez-Becerra C., et al. Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily. Trends Parasitol. 2009, 25(1):44-51.
110. Ferrante A., et al. Killing of Plasmodium falciparum by cytokine activated effector cells (neutrophils and macrophages). Immunol. Lett. 1990, 25(1-3):179-187.
111. Ferreira A., et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986, 232(4752):881-884.
112. Fleischhauer K., et al. Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. Tissue Antigens 1999, 53(6):519-526.
113. Frevert U., et al. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J. Exp. Med. 1993, 177(5):1287-1298.
114. Frevert U., et al. Plasmodium sporozoite passage across the sinusoidal cell layer. Subcell Biochem. 2008, 47:182-197.
115. Galinski M.R., Barnwell J.W. Plasmodium vivax: merozoites, invasion of reticulocytes and considerations for malaria vaccine development. Parasitol. Today 1996, 12(1):20-29.
116. Galinski M.R., Barnwell J.W. Plasmodium vivax: who cares?. Malar. J. 2008, 7(Suppl. 1):S9.
117. Galinski M.R., et al. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 1992, 69(7):1213-1226.
118. Galinski M.R., et al. Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. Mol. Biochem. Parasitol. 1999, 101(1-2):131-147.
119. Galinski M.R., et al. Plasmodium vivax merozoite surface proteins-3beta and-3gamma share structural similarities with P. vivax merozoite surface protein-3alpha and define a new gene family. Mol. Biochem. Parasitol. 2001, 115(1):41-53.
120. Galinski M., Dluzewski A., Barnwell J. Merozoite invasion of red blood cells. Molecular Approaches to Malaria 2005, 113-168. ASM Press, Washington, DC. S. IW (Ed.).
121. Gamage-Mendis A.C., et al. Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka. Parasite Immunol. 1992, 14(4):385-396.
122. Gantt S.M., et al. Cell adhesion to a motif shared by the malaria circumsporozoite protein and thrombospondin is mediated by its glycosaminoglycan-binding region and not by CSVTCG. J. Biol. Chem. 1997, 272(31):19205-19213.
123. Gao X., et al. Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites. PLoS Pathog. 2008, 4(7):e1000104.
124. Gaur D., Chitnis C.E. Molecular interactions and signaling mechanisms during erythrocyte invasion by malaria parasites. Curr. Opin. Microbiol. 2011, 14(4):422-428.
125. Gaur D., et al. Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasion. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(45):17789-17794.
126. Genton B., et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008, 5(6):e127.
127. Gerold P., et al. Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum. Mol. Biochem. Parasitol. 1996, 75(2):131-143.
128. Giha H.A., et al. Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol. Lett. 2000, 71(2):117-126.
129. Goncalves R.M., et al. CD4+ CD25+ Foxp3+ regulatory T cells, dendritic cells, and circulating cytokines in uncomplicated malaria: do different parasite species elicit similar host responses?. Infect. Immun. 2010, 78(11):4763-4772.
130. Grimberg B.T., et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 2007, 4(12):e337.
131. Guerra C.A., et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 2010, 4(8):e774.
132. Guilbride D.L., Guilbride P.D., Gawlinski P. Malaria's deadly secret: a skin stage. Trends Parasitol. 2012, 28(4):142-150.
133. Gunewardena D.M., Carter R., Mendis K.N. Patterns of acquired anti-malarial immunity in Sri Lanka. Mem. Inst. Oswaldo Cruz 1994, 89(Suppl. 2):63-65.
134. Gwadz R.W., Green I. Malaria immunization in Rhesus monkeys. A vaccine effective against both the sexual and asexual stages of Plasmodium knowlesi. J. Exp. Med. 1978, 148(5):1311-1323.
135. Gwadz R.W. Successful immunization against the sexual stages of Plasmodium gallinaceum. Science 1976, 193(4258):1150-1151.
136. Hafalla J.C., Silvie O., Matuschewski K. Cell biology and immunology of malaria. Immunol. Rev. 2011, 240(1):297-316.
137. Han H.J., et al. Epidermal growth factor-like motifs 1 and 2 of Plasmodium vivax merozoite surface protein 1 are critical domains in erythrocyte invasion. Biochem. Biophys. Res. Commun. 2004, 320(2):563-570.
138. Hansen D.S., Schofield L. Natural regulatory T cells in malaria: host or parasite allies?. PLoS Pathog. 2010, 6(4):e1000771.
139. Harris I., et al. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar. J. 2010, 9:254.
140. Healer J., et al. Transmission-blocking immunity to Plasmodium falciparum in malaria- immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 1999, 119(Pt 5):425-433.
141. Hedstrom R.C., et al. A malaria sporozoite surface antigen distinct from the circumsporozoite protein. Bull. World Health Organ 1990, 68.(Suppl):152-157.
142. Hemmer C.J., et al. Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels. Am. J. Med. 1991, 91(1):37-44.
143. Herrera M.A., et al. Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB/c mice. Mem. Inst. Oswaldo Cruz 1994, 89(Suppl. 2):71-76.
144. Herrera S., et al. Safety and elicitation of humoral and cellular responses in Colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am. J. Trop. Med. Hyg. 2005, 73(Suppl. 5):3-9.
145. Herrera S., et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am. J. Trop. Med. Hyg. 2011, 84(Suppl. 2):12-20.
146. Herrera S., Corradin G., Arevalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol. 2007, 23(3):122-128.
147. Hii J.L., et al. Area effects of bednet use in a malaria-endemic area in Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 2001, 95(1):7-13.
148. Hollingdale M.R., et al. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 1984, 132(2):909-913.
149. Horuk R., et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993, 261(5125):1182-1184.
150. Hossain M.E., Dhawan S., Mohmmed A. The cysteine-rich regions of Plasmodium falciparum RON2 bind with host erythrocyte and AMA1 during merozoite invasion. Parasitol. Res. 2012, 110(5):1711-1721.
151. Imwong M., et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis. 2007, 195(7):927-933.
152. Imwong M., et al. The first Plasmodium vivax relapses of life are usually genetically homologous. J. Infect. Dis. 2012, 205(4):680-683.
153. Iyer J.K., et al. Variable expression of the 235 kDa rhoptry protein of Plasmodium yoelii mediate host cell adaptation and immune evasion. Mol. Microbiol. 2007, 65(2):333-346.
154. Jangpatarapongsa K., et al. Memory T cells protect against Plasmodium vivax infection. Microbe. Infect. 2006, 8(3):680-686.
155. Jangpatarapongsa K., et al. Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur. J. Immunol. 2008, 38(10):2697-2705.
156. Jelinek T., et al. Imported falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin. Infect. Dis. 2002, 34(5):572-576.
157. John C.C., et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J. Immunol. 2004, 173(1):666-672.
158. John C.C., et al. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect. Immun. 2004, 72(9):5135-5142.
159. Jordan-Villegas A., et al. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am. J. Trop. Med. Hyg. 2011, 84(Suppl. 2):43-50.
160. Jordan-Villegas A., et al. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am. J. Trop. Med. Hyg. 2011, 84(Suppl. 2):43-50.
161. Joshi S.K., et al. Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India. Infect. Immun. 2000, 68(1):141-150.
162. Karunaweera N.D., et al. Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients. Clin. Exp. Immunol. 1992, 88(3):499-505.
163. Keen J.K., et al. A gene coding for a high-molecular mass rhoptry protein of Plasmodium yoelii. Mol. Biochem. Parasitol. 1994, 65(1):171-177.
164. Khan Z.M., Vanderberg J.P. Specific inflammatory cell infiltration of hepatic schizonts in BALB/c mice immunized with attenuated Plasmodium yoelii sporozoites. Int. Immunol. 1992, 4(7):711-718.
165. King C.L., et al. Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J. Immunol. 2002, 168(1):356-364.
166. King C.L., et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(24):8363-8368.
167. King C.L., et al. Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(50):20113-20118.
168. Klotz C., Frevert U. Plasmodium yoelii sporozoites modulate cytokine profile and induce apoptosis in murine Kupffer cells. Int. J. Parasitol. 2008, 38(14):1639-1650.
169. Koch R. Zusammenfassende Darstellung der Ergebnisse der Malaria Expedition. Dtsch. Med. Wochenschr. 1900, 26(49):781-783.
170. Koch R. Professor Koch's investigations on malaria: second report to the colonial department of the German Colonial Office. Br. Med. J. 1900, 325-327.
171. Koch R. Professor Koch's investigations on malaria: fourth report to the colonial department of the German Colonial Office. Br. Med. J. 1900, 1597-1598.
172. Koch R. Professor Koch's investigations on malaria: third report to the colonial department of the German Colonial Office. Br. Med. J. 1900, 1183-1186.
173. Koepfli, C., et al. A high force of blood-stage infection: a driver of the rapid natural acquisition of immunity to Plasmodium vivax in Papua New Guinean children? PLoS Neglected Trop. Dis., submitted for publication.
174. Korner H., et al. The role of TNF in parasitic diseases: still more questions than answers. Int. J. Parasitol. 2010, 40(8):879-888.
175. Kosaisavee V., et al. Genetic diversity in new members of the reticulocyte binding protein family in Thai Plasmodium vivax isolates. PLoS One 2012, 7(3):e32105.
176. Krotoski W.A. Discovery of the hypnozoite and a new theory of malarial relapse. Trans. R Soc. Trop. Med. Hyg. 1985, 79(1):1-11.
177. Kushwaha A., et al. Expression and characterisation of Plasmodium falciparum acidic basic repeat antigen expressed in Escherichia coli. Mol. Biochem. Parasitol. 2000, 106(2):213-224.
178. Lal A.A., et al. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infect. Immun. 1996, 64(3):1054-1059.
179. Lamarque M., et al. The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog. 2011, 7(2):e1001276.
180. Langhorne J., et al. Immunity to malaria: more questions than answers. Nat. Immunol. 2008, 9(7):725-732.
181. Lawpoolsri S., et al. The impact of human reservoir of malaria at a community-level on individual malaria occurrence in a low malaria transmission setting along the Thai-Myanmar border. Malar. J. 2010, 9:143.
182. Leech J.H., et al. Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes. J. Exp. Med. 1984, 159(6):1567-1575.
183. Lima-Junior J.C., et al. Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 2008, 26(51):6645-6654.
184. Lima-Junior J.C., et al. Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon. Vaccine 2010, 28(18):3185-3191.
185. Lima-Junior J.C., et al. B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon. Vaccine 2011, 29(9):1801-1811.
186. Lima-Junior J.C., et al. Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3alpha and MSP-9 in individuals from Brazilian endemic area. PLoS One 2012, 7(5):e36419.
187. Lin E., et al. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One 2010, 5(2):e9047.
188. Lyon J.A., Haynes J.D. Plasmodium falciparum antigens synthesized by schizonts and stabilized at the merozoite surface when schizonts mature in the presence of protease inhibitors. J. Immunol. 1986, 136(6):2245-2251.
189. Mackintosh C.L., et al. Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int. J. Parasitol. 2008, 38(12):1445-1454.
190. Mackroth M.S., et al. Human cord blood CD4+CD25hi regulatory T cells suppress prenatally acquired T cell responses to Plasmodium falciparum antigens. J. Immunol. 2011, 186(5):2780-2791.
191. Maitland K., et al. The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans. R Soc. Trop. Med. Hyg. 1996, 90(6):614-620.
192. Malhotra I., et al. Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of Plasmodium falciparum MSP1(33). J. Immunol. 2008, 180(5):3383-3390.
193. Malhotra I., et al. Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS Med. 2009, 6(7):e1000116.
194. Malik A., et al. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(8):3300-3304.
195. Manning L., et al. Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One 2012, 6:e29203.
196. Manwell R.D., Goldstein F. Passive immunity in avian malaria. J. Exp. Med. 1940, 71(3):409-423.
197. Marsh K., Howard R.J. Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science 1986, 231(4734):150-153.
198. Marsh K., et al. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R Soc. Trop. Med. Hyg. 1989, 83(3):293-303.
199. Matteelli A., et al. Epidemiological features and case management practices of imported malaria in northern Italy 1991-1995. Trop. Med. Int. Health 1999, 4(10):653-657.
200. Mazier D., et al. Hepatic phase of malaria: a crucial role as " go-between" with other stages. Bull. World Health Organ. 1990, 68(Suppl):126-131.
201. McGregor I.A., Wilson R.J.M. Specific immunity: acquired in man. Malaria. Principles and Practice of Malariology 1988, vol. 1.. Churchill Livingstone, Edinburgh. W.H. Wernsdorfer, I.A. McGregor (Eds.).
202. McGregor I.A. The passive transfer of human malarial immunity. Am. J. Trop. Med. Hyg. 1964, 13(Suppl):237-239.
203. Meis J.F.G., et al. The role of Küppfer cells in the trapping of malarial sporozoites in the liver and the subsequent infection of hepatocytes. Sinusoidal Liver Cells 1982, 429-436. Elsevier Biomedical Press, Amsterdam. D.L. Knook, E. Wisse (Eds.).
204. Mellouk S., et al. Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J. Immunol. 1987, 139(12):4192-4195.
205. Mellouk S., et al. Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bull. World Health Organ. 1990, 68(Suppl):52-59.
206. Mellouk S., et al. Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect. Immun. 1994, 62(9):4043-4046.
207. Menard D., et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(13):5967-5971.
208. Mendis K.N., Targett G.A. Immunisation against gametes and asexual erythrocytic stages of a rodent malaria parasite. Nature 1979, 277(5695):389-391.
209. Mendis K.N., et al. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect. Immun. 1987, 55(2):369-372.
210. Mendis K., et al. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001, 64:97-106.
211. Mendis K.N., Ihalamulla R.I., David P.H. Diversity of Plasmodium vivax-induced antigens on the surface of infected human erythrocytes. Am. J. Trop. Med. Hyg. 1988, 38(1):42-46.
212. Metenou S., et al. Fetal immune responses to Plasmodium falciparum antigens in a malaria-endemic region of Cameroon. J. Immunol. 2007, 178(5):2770-2777.
213. Meyer E.V., et al. The reticulocyte binding-like proteins of P. knowlesi locate to the micronemes of merozoites and define two new members of this invasion ligand family. Mol. Biochem. Parasitol. 2009, 165(2):111-121.
214. Michon P., et al. The risk of malarial infections and disease in Papua New Guinean children. Am. J. Trop. Med. Hyg. 2007, 76(6):997-1008.
215. Miller L.H., et al. Erythrocyte receptors for (Plasmodium knowlesi) malaria: duffy blood group determinants. Science 1975, 189(4202):561-563.
216. Miller L.H., et al. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 1976, 295(6):302-304.
217. Minigo G., et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog. 2009, 5(4):e1000402.
218. Moreno A., et al. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int. Immunol. 1991, 3(10):997-1003.
219. Morgan W.D., et al. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J. Mol. Biol. 1999, 289(1):113-122.
220. Mota M.M., et al. Migration of Plasmodium sporozoites through cells before infection. Science 2001, 291(5501):141-144.
221. Mourao L.C., et al. Naturally acquired antibodies to Plasmodium vivax blood-stage vaccine candidates PvMSP-1(1)(9) and PvMSP-3alpha(3)(5)(9)(-)(7)(9)(8) and their relationship with hematological features in malaria patients from the Brazilian Amazon. Microbe. Infect. 2012, 14(9):730-739.
222. Mueller I., et al. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar. J. 2009, 8:41.
223. Mueller I., et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 2009, 9(9):555-566.
224. Mueller I., et al. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(25):10030-10035.
225. Mufalo B.C., et al. Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection. Microbe. Infect. 2008, 10(12-13):1266-1273.
226. Muller I., et al. The epidemiology of malaria in Papua New Guinea. Trends Parasitol. 2003, 19(6):253-259.
227. Muller I., et al. Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar. J. 2009, 8:158.
228. Nardin E.H., Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 1993, 11:687-727.
229. Nichols M.E., et al. A new human Duffy blood group specificity defined by a murine monoclonal antibody. Immunogenetics and association with susceptibility to Plasmodium vivax. J. Exp. Med. 1987, 166(3):776-785.
230. Nogueira P.A., et al. A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect. Immun. 2006, 74(5):2726-2733.
231. Nussler A., et al. Inflammatory status and preerythrocytic stages of malaria: role of the C-reactive protein. Exp. Parasitol. 1991, 72(1):1-7.
232. Nussler A., et al. L-Arginine-dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin 6 stimulation. Eur. J. Immunol. 1991, 21(1):227-230.
233. Nussler A., et al. TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. Int. Immunol. 1991, 3(4):317-321.
234. Nussler A.K., et al. In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or adjuvants. Eur. J. Immunol. 1993, 23(4):882-887.
235. Okenu D.M., et al. The reticulocyte binding proteins of Plasmodium cynomolgi: a model system for studies of P. vivax. Mol. Biochem. Parasitol. 2005, 143(1):116-120.
236. Ord R.L., Tami A., Sutherland C.J. Ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency. PLoS One 2008, 3(10):e3366.
237. Overstreet M.G., et al. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol. Rev. 2008, 225:272-283.
238. Parashar A., et al. Cell mediated and humoral immunity in experimental Plasmodium berghei infection. Trans. R Soc. Trop. Med. Hyg. 1977, 71(6):474-480.
239. Peiris J.S., et al. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 1988, 39(1):26-32.
240. Perlaza B.L., et al. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides. Eur. J. Immunol. 2008, 38(9):2610-2615.
241. Perlaza B.L., et al. Interferon-gamma, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity. Malar. J. 2011, 10(1):27.
242. Phimpraphi W., et al. Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. Malar. J. 2008, 7:99.
243. Pied S., et al. C-reactive protein protects against preerythrocytic stages of malaria. Infect. Immun. 1989, 57(1):278-282.
244. Pied S., et al. Inhibitory activity of IL-6 on malaria hepatic stages. Parasite Immunol. 1991, 13(2):211-217.
245. Pied S., et al. Non specific resistance against malaria pre-erythrocytic stages: involvement of acute phase proteins. Parasite 1995, 2(3):263-268.
246. Pierce S.K. Understanding B cell activation: from single molecule tracking, through tolls, to stalking memory in malaria. Immunol. Res. 2009, 43(1-3):85-97.
247. Pizarro J.C., et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 2005, 308(5720):408-411.
248. Poespoprodjo J.R., et al. Vivax malaria: a major cause of morbidity in early infancy. Clin. Infect. Dis. 2009, 48(12):1704-1712.
249. Premawansa S., et al. Target antigens of transmission blocking immunity of Plasmodium vivax malaria. Characterization and polymorphism in natural parasite isolates. J. Immunol. 1990, 144(11):4376-4383.
250. Premawansa S., et al. Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka. Parasite Immunol. 1994, 16(1):35-42.
251. Putaporntip C., et al. Nucleotide sequence polymorphism at the apical membrane antigen-1 locus reveals population history of Plasmodium vivax in Thailand. Infect. Genet. Evol. 2009, 9(6):1295-1300.
252. Ramsey J.M., Salinas E., Rodriguez M.H. Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am. J. Trop. Med. Hyg. 1996, 54(5):458-463.
253. Rayner J.C., et al. Two Plasmodium falciparum genes express merozoite proteins that are related to Plasmodium vivax and Plasmodium yoelii adhesive proteins involved in host cell selection and invasion. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(17):9648-9653.
254. Rayner J.C., et al. Extensive polymorphism in the Plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domains. Parasitology 2002, 125(Pt 5):393-405.
255. Rayner J.C., et al. Plasmodium vivax merozoite surface protein PvMSP-3 beta is radically polymorphic through mutation and large insertions and deletions. Infect. Genet. Evol. 2004, 4(4):309-319.
256. Rayner J.C., et al. Rapid evolution of an erythrocyte invasion gene family: the Plasmodium reichenowi Reticulocyte Binding like (RBL) genes. Mol. Biochem. Parasitol. 2004, 133(2):287-296.
257. Rayner J.C., et al. Dramatic difference in diversity between Plasmodium falciparum and Plasmodium vivax reticulocyte binding-like genes. Am. J. Trop. Med. Hyg. 2005, 72(6):666-674.
258. Rayner J.C., Huber C.S., Barnwell J.W. Conservation and divergence in erythrocyte invasion ligands: Plasmodium reichenowi EBL genes. Mol. Biochem. Parasitol. 2004, 138(2):243-247.
259. Reece W.H., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 2004, 10(4):406-410.
260. Remarque E.J., et al. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 2008, 76(6):2660-2670.
261. Remarque E.J., et al. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008, 24(2):74-84.
262. Remarque E.J., et al. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS One 2012, 7(6):e38898.
263. Renia L., et al. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J. Immunol. 1993, 150(4):1471-1478.
264. Renia L. Protective immunity against malaria liver stage after vaccination with live parasites. Parasite 2008, 15(3):379-383.
265. Rieckmann K.H. Human immunization with attenuated sporozoites. Bull. World Health Organ. 1990, 68(Suppl):13-16.
266. Rodrigues M.M., et al. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 1991, 3(6):579-585.
267. Rodrigues M.H., et al. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int. J. Parasitol. 2005, 35(2):185-192.
268. Rodriguez M., et al. PfRH5: a novel reticulocyte-binding family homolog of Plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS One 2008, 3(10):e3300.
269. Roeffen W., et al. Transmission blocking immunity as observed in a feeder system and serological reactivity to Pfs 48/45 and Pfs230 in field sera. Mem. Inst. Oswaldo Cruz 1994, 89(Suppl. 2):13-15.
270. Rogerson S.J., Mwapasa V., Meshnick S.R. Malaria in pregnancy: linking immunity and pathogenesis to prevention. Am. J. Trop. Med. Hyg. 2007, 77(Suppl. 6):14-22.
271. Romero P., et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341(6240):323-326.
272. Rosanas-Urgell A., et al. Reduced risk of Plasmodium vivax malaria in Papua new Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Medicine 2012, 9(9):e1001305.
273. Rosas-Acosta G. Identification of Erythrocyte Binding Regions within the Reticulocyte Binding Proteins of Plasmodium vivax 1998, New York University, New York.
274. Rosenberg R., et al. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans. R. Soc. Trop. Med. Hyg. 1990, 84(2):209-212.
275. Rudin W., et al. Interferon-gamma is essential for the development of cerebral malaria. Eur. J. Immunol. 1997, 27(4):810-815.
276. Russell B., et al. A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood 2011, 118(13):e74-81.
277. Salmon B.L., Oksman A., Goldberg D.E. Malaria parasite exit from the host erythrocyte: a two-step process requiring extraerythrocytic proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(1):271-276.
278. Sattabongkot J., et al. Comparison of artificial membrane feeding with direct skin feeding to estimate the infectiousness of Plasmodium vivax gametocyte carriers to mosquitoes. Am. J. Trop. Med. Hyg. 2003, 69(5):529-535.
279. Scheller L.F., Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(9):4066-4068.
280. Scherf A., Lopez-Rubio J.J., Riviere L. Antigenic variation in Plasmodium falciparum. Annu. Rev. Microbiol. 2008, 62:445-470.
281. Schofield L., et al. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J. Immunol. 1987, 139(6):2020-2025.
282. Scholzen A., et al. Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog. 2009, 5(8):e1000543.
283. Scholzen A., Minigo G., Plebanski M. Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol. 2010, 26(1):16-25.
284. Schwenk R., et al. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol. 2003, 25(1):17-25.
285. Sedegah M., Finkelman F., Hoffman S.L. Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(22):10700-10702.
286. Seguin M.C., et al. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J. Exp. Med. 1994, 180(1):353-358.
287. Semenya A.A., et al. Two functional reticulocyte binding-like (RBL) invasion ligands of zoonotic Plasmodium knowlesi exhibit differential adhesion to monkey and human erythrocytes. Malar. J. 2012, 11:228.
288. Senn N., et al. Efficacy of intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax. PLoS Med. 2012, 9:e1001195.
289. Seth R.K., et al. Acquired immune response to defined Plasmodium vivax antigens in individuals residing in northern India. Microbe. Infect. 2010, 12(3):199-206.
290. Sheehy S.H., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012, 7(2):e31208.
291. Shute P.G., et al. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans. R. Soc. Trop. Med. Hyg. 1976, 70(5-6):474-481.
292. Sidjanski S., Vanderberg J.P. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am. J. Trop. Med. Hyg. 1997, 57(4):426-429.
293. Sierra A.Y., et al. Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Vaccine 2003, 21(27-30):4133-4144.
294. Singh A.P., et al. Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion. Mol. Microbiol. 2005, 55(6):1925-1934.
295. Singh S., et al. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum. PLoS One 2009, 4(4):e5410.
296. Sinnis P., et al. Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J. Exp. Med. 1994, 180(1):297-306.
297. Sirima S.B., Cousens S., Druilhe P. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med. 2011, 365(11):1062-1064.
298. Smith J.D., et al. Decoding the language of var genes and Plasmodium falciparum sequestration. Trends Parasitol. 2001, 17(11):538-545.
299. Snewin V.A., et al. Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector. J. Exp. Med. 1995, 181(1):357-362.
300. Soares I.S., Rodrigues M.M. Immunogenic properties of the Plasmodium vivax vaccine candidate MSP1(19) expressed as a secreted non-glycosylated polypeptide from Pichia pastoris. Parasitology 2002, 124(Pt 3):237-246.
301. Soares I.S., et al. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect. Immun. 1997, 65(5):1606-1614.
302. Soares I.S., et al. Antibody response to the N and C-terminal regions of the Plasmodium vivax merozoite surface protein 1 in individuals living in an area of exclusive transmission of P. vivax malaria in the north of Brazil. Acta Trop. 1999, 72(1):13-24.
303. Srinivasan P., et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(32):13275-13280.
304. Struik S.S., Riley E.M. Does malaria suffer from lack of memory?. Immunol. Rev. 2004, 201:268-290.
305. Su X.Z., et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995, 82(1):89-100.
306. Suhrbier A., et al. Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria. Am. J. Trop. Med. Hyg. 1989, 40(4):351-355.
307. Sultan A.A., et al. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 1997, 90(3):511-522.
308. Sutherland C.J. Surface antigens of Plasmodium falciparum gametocytes-a new class of transmission-blocking vaccine targets?. Mol. Biochem. Parasitol. 2009, 166(2):93-98.
309. Suwanarusk R., et al. The deformability of red blood cells parasitized by Plasmodium falciparum and P. vivax. J. Infect. Dis. 2004, 189(2):190-194.
310. Takita-Sonoda Y., et al. Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein. Exp. Parasitol. 1996, 84(2):223-230.
311. Taliaferro W.H. Immunity to the Malaria Infections, in Malariology 1949, 935-965. W.B. Saunders, Philadelphia. M.F. Boyd (Ed.).
312. ter Kuile F.O., Rogerson S.J. Plasmodium vivax infection during pregnancy: an important problem in need of new solutions. Clin. Infect. Dis. 2008, 46(9):1382-1384.
313. Thakur A., et al. Plasmodium vivax: sequence polymorphism and effect of natural selection at apical membrane antigen 1 (PvAMA1) among Indian population. Gene 2008, 419(1-2):35-42.
314. Tjitra E., et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008, 5(6):e128.
315. Tran T.M., et al. Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am. J. Trop. Med. Hyg. 2005, 73(2):244-255.
316. Trieu A., et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol. Cell. Proteomics 2011, 10(9). M111 007948.
317. Triglia T., et al. Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins in Plasmodium vivax. Infect. Immun. 2001, 69(2):1084-1092.
318. Triglia T., et al. Plasmodium falciparum merozoite invasion is inhibited by antibodies that target the PfRh2a and b binding domains. PLoS Pathog. 2011, 7(6):e1002075.
319. Tsuboi T., et al. Transmission-blocking vaccine of vivax malaria. Parasitol. Int. 2003, 52(1):1-11.
320. Tsuboi T., et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 2008, 76(4):1702-1708.
321. Tsuboi T., et al. An efficient approach to the production of vaccines against the malaria parasite. Methods Mol. Biol. 2010, 607:73-83.
322. Tsuboi T., et al. The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery. Acta Trop. 2010, 114(3):171-176.
323. Tsuji M., Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol. 2003, 19(2):88-93.
324. Tsuji M., et al. CD4+ cytolytic T cell clone confers protection against murine malaria. J. Exp. Med. 1990, 172(5):1353-1357.
325. Tsuji M., et al. Development of antimalaria immunity in mice lacking IFN-gamma receptor. J. Immunol. 1995, 154(10):5338-5344.
326. Udomsangpetch R., et al. Short-term in vitro culture of field isolates of Plasmodium vivax using umbilical cord blood. Parasitol. Int. 2007, 56(1):65-69.
327. Udomsangpetch R., et al. Cultivation of Plasmodium vivax. Trends Parasitol. 2008, 24(2):85-88.
328. Urquiza M., et al. Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes. Peptides 2002, 23(12):2265-2277.
329. Valderrama-Aguirre A., et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am. J. Trop. Med. Hyg. 2005, 73(Suppl. 5):16-24.
330. VanBuskirk K.M., et al. Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies. J. Infect. Dis. 2004, 190(9):1556-1562.
331. Vanderberg J., Nussenzweig R., Most H. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil Med. 1969, 134(10):1183-1190.
332. Vargas-Serrato E., et al. Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p.101/ABRA of P. falciparum. Mol. Biochem. Parasitol. 2002, 120(1):41-52.
333. Vinetz J.M., Gilman R.H. Asymptomatic Plasmodium parasitemia and the ecology of malaria transmission. Am. J. Trop. Med. Hyg. 2002, 66(6):639-640.
334. Voza T., et al. Extrahepatic exoerythrocytic forms of rodent malaria parasites at the site of inoculation: clearance after immunization, susceptibility to primaquine, and contribution to blood-stage infection. Infect. Immun. 2012, 80(6):2158-2164.
335. Vreden S.G., et al. Kupffer cell elimination enhances development of liver schizonts of Plasmodium berghei in rats. Infect. Immun. 1993, 61(5):1936-1939.
336. Walther M., et al. Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog. 2009, 5(4):e1000364.
337. Weiss W.R., et al. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(2):573-576.
338. Weiss G.E., et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J. Immunol. 2009, 183(3):2176-2182.
339. Weiss G.E., et al. The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog. 2010, 6(5):e1000912.
340. Wernsdorfer W.H., McGregor S.I. Malaria: Principles and Practice Malariolog 1988, Churchill Livingstone, Edinburg, 61-96.
341. Wertheimer S.P., Barnwell J.W. Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp. Parasitol. 1989, 69(4):340-350.
342. White N.J. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar. J. 2011, 10:297.
343. Wickramarachchi T., et al. Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka. Infect. Immun. 2006, 74(1):798-801.
344. Wipasa J., et al. Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 2010, 6(2):e1000770.
345. Xainli J., et al. Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect. Immun. 2003, 71(5):2508-2515.
346. Yang C., et al. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant. Infect. Immun. 1999, 67(1):342-349.
347. Zevering Y., et al. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(13):6118-6122.
348. Zeyrek F.Y., et al. Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa, Turkey. Am. J. Trop. Med. Hyg. 2008, 78(5):729-732.